{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:40:28Z","timestamp":1789011628707,"version":"build-2803163510"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study systematically assessed the efficacy and safety of 15 incretin-based therapies (IBTs) for type 2 diabetes mellitus (T2DM), including mono- (GLP-1RA), dual- (GIP\/GLP-1RA or GLP-1\/GCGR), and triple- (GIP\/GLP-1\/GCGR) receptor agonists, and explored how dosage and treatment duration affect clinical outcomes to support individualized treatment decisions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review and Bayesian network meta-analysis were performed following PRISMA 2020 and PRISMA-NMA guidelines (PROSPERO: CRD420251152746). We searched MEDLINE, Cochrane Library, and Embase up to 1 August 2025, for randomized controlled trials (RCTs). Study selection, data extraction, risk-of-bias assessment (Cochrane RoB 2.0) and CINeMA framework were conducted. Analyses included SUCRA ranking, sensitivity, subgroup, and meta-regression in R Studio 4.4.3.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>102 RCTs (98,693 T2DM patients) with low overall bias were included. IBTs were superior to placebo in glycemic control (tirzepatide, orforglipron, semaglutide best), weight loss (retatrutide best), lipid, blood pressure, cardiorenal, and insulin function improvement. The most common adverse events were mild, transient gastrointestinal reactions, and the risk of hypoglycemia was low. Higher doses improved efficacy but increased adverse events; 45\u00a0mg orforglipron balanced benefits and tolerability. Optimal duration and combination efficacy varied by agent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IBTs provide comprehensive benefits in T2DM. Efficacy and safety differ across agents, doses, durations, and combinations, supporting individualized therapy. Long-term high-quality RCTs are needed. Cardiovascular protection may stem from synergistic improvements in lipids, blood pressure, renal function, and insulin sensitivity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD420251152746.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1846714","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:33:57Z","timestamp":1781757237000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus: a network meta-analysis based on clinical trials"],"prefix":"10.3389","volume":"17","author":[{"given":"Xichao","family":"Wu","sequence":"first","affiliation":[{"name":"Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, Shandong Engineering and Technology Research Center for Pediatric Drug Development, The First Affiliated Hospital of Shandong First Medical University \/ Shandong Qianfoshan Hospital","place":["Jinan, China"]},{"name":"School of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan","place":["Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiao","family":"Yang","sequence":"additional","affiliation":[{"name":"Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, Shandong Engineering and Technology Research Center for Pediatric Drug Development, The First Affiliated Hospital of Shandong First Medical University \/ Shandong Qianfoshan Hospital","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Cui","sequence":"additional","affiliation":[{"name":"Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, Shandong Engineering and Technology Research Center for Pediatric Drug Development, The First Affiliated Hospital of Shandong First Medical University \/ Shandong Qianfoshan Hospital","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Li","sequence":"additional","affiliation":[{"name":"Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, Shandong Engineering and Technology Research Center for Pediatric Drug Development, The First Affiliated Hospital of Shandong First Medical University \/ Shandong Qianfoshan Hospital","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[{"name":"Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, Shandong Engineering and Technology Research Center for Pediatric Drug Development, The First Affiliated Hospital of Shandong First Medical University \/ Shandong Qianfoshan Hospital","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/dom.12539","article-title":"Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial","volume":"17","author":"Ahmann","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"B2","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.2337\/dc25-S011","article-title":"Standards of care in Diabetes\u20142025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1016\/S0140-6736(15)60936-9","article-title":"Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study","volume":"385","author":"Blonde","year":"2015","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12916-025-03890-w","article-title":"Global, regional, and national burdens of type 1 and type 2 diabetes mellitus in adolescents from 1990 to 2021, with forecasts to 2030: a systematic analysis of the global burden of disease study 2021","volume":"23","author":"Chen","year":"2025","journal-title":"BMC Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00592-024-02300-6","article-title":"GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes","volume":"61","author":"Ciardullo","year":"2024","journal-title":"Acta Diabetol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"108077","DOI":"10.1016\/j.phrs.2025.108077","article-title":"IUPHAR review: from foe to friend: repurposing glucagon to treat obesity and type 2 diabetes","volume":"223","author":"Elmendorf","year":"2026","journal-title":"Pharmacol. Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"B9","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"796","DOI":"10.3390\/biom15060796","article-title":"Retatrutide\u2014A game changer in obesity pharmacotherapy","volume":"15","author":"Katsi","year":"2025","journal-title":"Biomolecules"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1431292","DOI":"10.3389\/fendo.2024.1431292","article-title":"Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists","volume":"15","author":"Liu","year":"2024","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1080\/00273171.2022.2115965","article-title":"A gentle introduction to Bayesian network meta-analysis using an automated R package","volume":"58","author":"Liu","year":"2023","journal-title":"Multivar. Behav. Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"111884","DOI":"10.1016\/j.diabres.2024.111884","article-title":"Analysis of the global burden of CKD-T2DM in young and middle-aged adults in 204 countries and territories from 2000 to 2019: a systematic study of the global burden of disease in 2019","volume":"217","author":"Liu","year":"2024","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B14","doi-asserted-by":"publisher","first-page":"117545","DOI":"10.1016\/j.atherosclerosis.2024.117545","article-title":"Modification of lipoprotein metabolism and function driving atherogenesis in diabetes","volume":"394","author":"Luciani","year":"2024","journal-title":"Atherosclerosis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1464-5491.2009.02666.x","article-title":"Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)","volume":"26","author":"Marre","year":"2009","journal-title":"Diabet. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2215\/CJN.0000000584","article-title":"The impact of glucagon-like peptide-1 receptor agonists on kidney outcomes: a meta-analysis of randomized placebo-controlled trials","volume":"20","author":"Mendon\u00e7a","year":"2025","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3760\/cma.j.cn112138-20250924-00572","article-title":"Guidelines for the prevention and treatment of diabetes in China (2024 edition)","volume":"17","year":"2025","journal-title":"Chin. J. Diabetes Mellit."},{"key":"B18","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1515\/ijb-2022-0121","article-title":"Bayesian estimation and prediction for network meta-analysis with contrast-based approach","volume":"20","author":"Noma","year":"2023","journal-title":"Int. J. Biostat."},{"key":"B19","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/jdi.12478","article-title":"Mechanisms underlying glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 secretion","volume":"7","author":"Reimann","year":"2016","journal-title":"J. Diabetes Investig."},{"key":"B21","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1111\/j.1463-1326.2012.01618.x","article-title":"EFC10887 GETGOAL-L Asia study investigators. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)","volume":"14","author":"Seino","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e70003","DOI":"10.1002\/cph4.70003","article-title":"Type 2 diabetes mellitus: a comprehensive review of pathophysiology, comorbidities, and emerging therapies","volume":"15","author":"Singh","year":"2025","journal-title":"Compr. Physiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"17562864241281903","DOI":"10.1177\/17562864241281903","article-title":"Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP\/GLP-1 receptor agonist tirzepatide in overweight or Obese adults without diabetes: a systematic review and meta-analysis","volume":"17","author":"Stefanou","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"B25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/bmj.323.7304.101","article-title":"Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis","volume":"323","author":"Sterne","year":"2001","journal-title":"BMJ"},{"key":"B26","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B27","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3390\/biom15020213","article-title":"From cardiovascular-kidney-metabolic syndrome to cardiovascular-renal-hepatic-metabolic syndrome: proposing an expanded framework","volume":"15","author":"Theodorakis","year":"2025","journal-title":"Biomolecules"},{"key":"B28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nrneph.2015.173","article-title":"Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease","volume":"12","author":"Thomas","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1167","article-title":"Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis","volume":"7","author":"van Valkenhoef","year":"2016","journal-title":"Res. Synth. Methods"},{"key":"B30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jdiacomp.2016.08.018","article-title":"Incretin-based therapy in type 2 diabetes: an evidence based systematic review and meta-analysis","volume":"32","author":"Waldrop","year":"2018","journal-title":"J. Diabetes Complicat."},{"key":"B31","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/dom.13613","article-title":"The effects of incretin-based therapies on \u03b2-cell function and insulin resistance in type 2 diabetes: a systematic review and network meta-analysis combining 360 trials","volume":"21","author":"Wu","year":"2019","journal-title":"Diabetes Obes. Metab."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1846714\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:34:07Z","timestamp":1781757247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1846714\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":31,"alternative-id":["10.3389\/fphar.2026.1846714"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1846714","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"article-number":"1846714"}}